For older adults diagnosed with acute myeloid leukemia (AML), the path to survival has long been obstructed by a cruel biological paradox: the very treatment most likely to cure the disease—hematopoietic stem cell transplantation—is often too aggressive for the patients who need it most.
Because AML predominantly affects adults with a median age of onset between 65 and 68, most patients present with reduced physiological reserves and comorbidities that make them ineligible for the intensive conditioning regimens required for a full transplant. For these patients, the global long-term survival rate has historically hovered between 20% and 30%, leaving a massive void in clinical care.
However, fresh clinical evidence suggests a promising alternative. Research led by Professor Junmin Li of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, indicates that umbilical cord blood therapy for elderly patients with acute myeloid leukemia—administered as an infusion rather than a full transplant—may significantly improve survival outcomes by modulating the immune system without the toxicity of traditional stem cell transplants.
Presented during the 9th Beijing Conference on Thrombosis and Hemostasis and the 7th Beijing Hematologic Oncology and Immunology Summit Forum, Professor Li’s findings suggest that combining moderate-intensity chemotherapy with umbilical cord blood infusions can, in some cases, double the overall survival rate compared to chemotherapy alone.
The Barrier to Conventional Stem Cell Transplants
In standard hematologic oncology, a hematopoietic stem cell transplant (HSCT) is the gold standard for achieving long-term remission. However, the process requires “conditioning”—intensive myeloablation and lymphodepletion—to clear the patient’s bone marrow and prevent the rejection of new cells. For an elderly patient, this process can be catastrophic, often leading to organ failure or lethal infections.
This creates a clinical bottleneck where only a small fraction of elderly AML patients are physically capable of tolerating the procedure. While the introduction of small-molecule targeted agents, such as BCL-2 inhibitors, has helped manage the disease, the median overall survival for this population remains approximately 18 months.
Professor Li argues that the medical community must move beyond the binary choice of “intensive transplant” or “palliative chemotherapy,” seeking a middle ground that leverages cellular therapy without the extreme physiological cost.
A New Paradigm: Infusion vs. Transplantation
The strategy employed at Ruijin Hospital differs fundamentally from a conventional transplant. Rather than attempting to completely replace the patient’s hematopoietic system, the team utilizes umbilical cord blood as a form of immunotherapy.
Umbilical cord blood is exceptionally rich in immunologically active cells. When infused alongside non-intensive or moderate-intensity chemotherapy, these cells appear to stimulate the patient’s residual immune system, enhancing its functional capacity to fight leukemia. The therapy helps optimize the hematopoietic microenvironment—the “soil” in which blood cells grow—making it less hospitable to cancer cells and more supportive of healthy blood production.
This approach shifts the goal from total marrow replacement to immune modulation, potentially reducing the risk of severe graft-versus-host disease (GVHD) and the profound infections typically associated with high-dose lymphodepletion.
Measuring Clinical Impact
Based on more than a decade of clinical investigation, Professor Li’s team has observed a marked increase in long-term survival rates. While standard care often results in limited durability, the addition of cord blood infusions to targeted treatment regimens may increase long-term survival rates to approximately 40% to 50%.
| Feature | Conventional HSCT | Cord Blood Infusion Therapy |
|---|---|---|
| Conditioning Intensity | High (Myeloablative) | Moderate to Low |
| Organ Requirement | Strictly Preserved | More Flexible |
| Primary Mechanism | System Replacement | Immune Modulation |
| Patient Eligibility | Limited/Strict | Broader |
Despite these gains, Professor Li notes that the precise biological mechanisms are still being mapped. In a departure from the traditional evidence-based medicine model—where the mechanism is usually fully understood before clinical application—the benefits of cord blood infusion are emerging first, with the research into how it works following closely behind.
Overcoming Bottlenecks in Clinical Adoption
For this therapy to become a standard of care, several hurdles remain. The most immediate is awareness; many clinicians and patients are unfamiliar with the distinction between a full transplant and an infusion therapy. Without this clarity, eligible patients may be prematurely ruled out of cellular therapy options.
the scalability of the treatment depends on donor matching and the accessibility of high-quality cord blood banks. However, because this approach is less dependent on a perfect HLA (human leukocyte antigen) match than a full transplant, it may offer a faster route to treatment for patients whose disease is progressing rapidly.
The future of these modalities is currently aligned with broader national strategic priorities. As cellular and gene therapies receive increased funding and regulatory support, the infrastructure for cord blood collection and infusion is expected to expand, potentially lowering costs and increasing technical accessibility across various healthcare tiers.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult with a board-certified hematologist or oncologist to determine the appropriate treatment plan for their specific condition.
The next phase of development will involve larger, multi-center trials to refine the “knowledge framework” of cord blood infusions and establish standardized protocols for moderate-intensity chemotherapy combinations. These iterative studies will be critical in determining the exact patient profiles that benefit most from this immunotherapy.
We invite readers to share their experiences with AML treatment or request questions about emerging cellular therapies in the comments below.
